Radio-Immuno-Modulation in Lung Cancer
- Conditions
- Lung Cancer
- Interventions
- Biological: Patients with a living donorBiological: Patients with a UCB donor
- Registration Number
- NCT02579005
- Lead Sponsor
- Hopital du Sacre-Coeur de Montreal
- Brief Summary
This project will assess the feasibility of treating advanced cancer using the immune system, without any anti-cancer drug. In this pilot study, the investigators propose combining low-dose radiotherapy, in lung cancer patients, with allogeneic immune cells obtained from a donor. The patients will receive radiotherapy directed to one of the patient's tumors, as well as an immunomodulatory drug called cyclophosphamide. Thereafter, they will receive the infusion of donor immune cells.
- Detailed Description
Metastatic lung cancer remains incurable despite numerous studies and treatments tried, including chemotherapy and, more recently, targeted therapies.
Cancer can escape immune surveillance through different mechanisms: low levels of tumor associated antigens (TAA), regulatory T cells, and immunosuppressive cytokines. Non-cytolytic doses of radiation have been shown to reverse some of these pathways in experimental models. It up-regulated the density of the MHC molecules presenting TAA and increased the T cell infiltration of the tumor (1). Patients with lymphoma, liver or prostate cancer were treated with radiotherapy combined with immunotherapy, in the form of a TLR9 agonist, autologous dendritic cells or a prostate-specific antigen vaccine (2, 3, 4). These trials have shown an induction of T cell reactivity against TAA. Another form of immunotherapy, used for patients with refractory hematologic malignancies is allogeneic hematopoietic stem cell transplantation (HSCT) (5). Its success has relied on cell infusions from a donor, demonstrating the immunologic control sustained by allogeneic cells (6).
The approach investigated in this study uses the immune cells from a donor to induce a tumor destruction reaction. This will be amplified by the immunological effects of radiotherapy. Many oncogenes are present in lung cancers and low-dose radiation increases their expression on the surface of the tumor cell. In addition, radiation has the property to stimulate the production of inflammatory cytokines and chemokines in the irradiated site. Finally, the donor's immune cells shall respond physiologically by migrating to the site of inflammation. This will trigger an immune reaction directed against the abnormal cancer cells.
A total of 24 patients are expected to be recruited over the study period, estimated to be 3 years. The allogeneic cells will be obtained from one of two possible donor types. For patients having a living donor, the immune cells will be harvested through a collection procedure called apheresis. The living donor should be a sibling with 3/6 or less HLA compatibility with the patient, at the A, B and DRB1 loci. For patients who do not have such a living donor, allogeneic cells from a cryopreserved umbilical cord blood (UCB) unit will be used.
The treatment course will be the following: low-dose radiotherapy will be delivered to a single tumor site, which could be either the primary tumor or one of its metastases. Low-dose cyclophosphamide will be given to decrease regulatory T cell activity and increase anti-tumor responses. Allogeneic immune cells will be administered thereafter, according to the treatment arm the patient has been assigned.
Recruitment & Eligibility
- Status
- SUSPENDED
- Sex
- All
- Target Recruitment
- 24
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Patients with a living donor Patients with a living donor Radiation + PBMC Patients with a UCB donor Patients with a UCB donor Radiation + UCB
- Primary Outcome Measures
Name Time Method Incidence of treatment-related adverse events Up to 6 months Evaluation by follow-up clinic visits, including medical questionnaire, physical exam \& blood tests: complete blood count, electrolytes, renal \& liver function tests. AE will be graded using National Cancer Institute's Common Toxicity Criteria version 3 (7). Evaluations will take place twice a week for the first 2 weeks, weekly for 2 weeks, every 2 weeks for 2 months \& every month for 3 months. It is anticipated that a maximum of 1 of 6 patients will have grade 3 side effects, including nausea, diarrhea, dyspnea, cough, fever, rash.
- Secondary Outcome Measures
Name Time Method Immune responses - T cell infiltration Up to 1 month Assessment using biopsies done before \& 1-2 weeks after treatment. The block slides will be stained with CD3, CD4, CD8 \& PDL-1 antibodies. T cell density will be expressed as the number of CD4+ and CD8+ cells to tumor cell ratio. The degree of T cell infiltration of the tumors will be assessed by comparing these ratios between pre \& post treatment samples.
Immune responses - tumor infiltrating T cell phenotype Up to 1 month Assessment using biopsies done before \& 1-2 weeks after treatment. Flow cytometry will be used to assess the following markers on tumor infiltrating T cells: CD3, CD4, CD8, CD25 \& Foxp3. The nature and magnitude of T cell infiltration will be assessed by comparing the frequencies of these T cell subsets between pre \& post treatment samples.
Immune responses - Tumor cell phenotype Up to 1 month Assessment using biopsies done before \& 1-2 weeks after treatment. Flow cytometry will be used to assess the following tumor markers: HLA, Fas, ICAM-1, PDL-1. The changes in tumor cell phenotypes will be assessed by comparing the mean fluorescence intensity of the above markers between pre \& post treatment samples. The PDL-1 tumor cell expression will also be compared on the block slides between pre \& post treatment samples.
Immune responses - origin of tumor infiltrating T cells Up to 1 month Assessment using biopsies done 1-2 weeks after treatment. Single cell suspensions will be stained with the following markers for tumor infiltrating T cells: CD3, CD4 and CD8. CD4+ and CD8+ T cells will be isolated by fluorescence-activated cell sorting. Their origin (patient vs donor) will be determined by a chimerism assay. The frequencies of donor-derived cells will be determined by PCR quantification of patient and donor specific VNTR bands.
Trial Locations
- Locations (1)
Hopital Sacre-Coeur
🇨🇦Montréal, Quebec, Canada